Epidemiology and Public Health, College of Medicine and Health, University of Exeter, Exeter EX1 2LU, UK.
Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
Age Ageing. 2021 Feb 26;50(2):457-464. doi: 10.1093/ageing/afaa147.
treatment of dementia in individuals with comorbidities is complex, leading to potentially inappropriate prescribing (PIP). The impact of PIP in this population is unknown.
to estimate the rate of PIP and its effect on adverse health outcomes (AHO).
retrospective cohort.
primary care electronic health records linked to hospital discharge data from England.
11,175 individuals with dementia aged over 65 years in 2016 and 43,463 age- and sex-matched controls.
Screening Tool of Older Persons' Prescriptions V2 defined PIP. Logistic regression tested associations with comorbidities at baseline, and survival analyses risk of incident AHO, adjusted for age, gender, deprivation and 14 comorbidities.
the dementia group had increased risk of PIP (73% prevalence; odds ratio [OR]: 1.92; confidence interval [CI]: 83-103%; P < 0.01) after adjusting for comorbidities. Most frequent PIP criteria were related to anti-cholinergic drugs and therapeutic duplication. Risk of PIP was higher in patients also diagnosed with coronary-heart disease (odds OR: 2.17; CI: 1.91-2.46; P < 0.01), severe mental illness (OR: 2.09; CI: 1.62-2.70; P < 0.01); and depression (OR: 1.81; CI: 1.62-2.01; P < 0.01). During follow-up (1 year), PIP was associated with increased all-cause mortality (hazard ratio: 1.14; CI: 1.02-1.26; P < 0.02), skin ulcer and pressure sores (hazard ratio: 1.66; CI: 1.12-2.46; P < 0.01), falls (hazard ratio: 1.37; CI: 1.15-1.63; P < 0.01), anaemia (hazard ratio: 1.61; CI: 1.10-2.38; P < 0.02) and osteoporosis (hazard ratio: 1.62; CI: 1.02-2.57; P < 0.04).
patients with dementia frequently receive PIPs, and those who do are more likely to experience AHO. These results highlight the need to optimise medication in dementia patients, especially those with comorbidities.
合并症患者的痴呆症治疗较为复杂,可能导致潜在的不适当处方(PIP)。目前尚不清楚这种人群中 PIP 的影响。
评估 PIP 的发生率及其对不良健康结局(AHO)的影响。
回顾性队列研究。
英格兰的初级保健电子健康记录与医院出院数据相关联。
2016 年 11175 名年龄在 65 岁以上患有痴呆症的个体和 43463 名年龄和性别匹配的对照者。
老年人处方筛选工具 2 版定义了 PIP。使用逻辑回归检验了基线合并症的关联,并对年龄、性别、贫困和 14 种合并症进行了调整,对新发 AHO 的风险进行了生存分析。
在调整了合并症后,痴呆组的 PIP 发生率较高(73%的患病率;比值比 [OR]:1.92;置信区间 [CI]:83-103%;P<0.01)。最常见的 PIP 标准与抗胆碱能药物和治疗重复有关。在还被诊断为冠心病(OR:2.17;CI:1.91-2.46;P<0.01)、严重精神疾病(OR:2.09;CI:1.62-2.70;P<0.01)和抑郁症(OR:1.81;CI:1.62-2.01;P<0.01)的患者中,PIP 的风险更高。在随访期间(1 年),PIP 与全因死亡率增加相关(风险比:1.14;CI:1.02-1.26;P<0.02)、皮肤溃疡和压疮(风险比:1.66;CI:1.12-2.46;P<0.01)、跌倒(风险比:1.37;CI:1.15-1.63;P<0.01)、贫血(风险比:1.61;CI:1.10-2.38;P<0.02)和骨质疏松症(风险比:1.62;CI:1.02-2.57;P<0.04)有关。
痴呆症患者经常接受 PIP 治疗,而接受 PIP 治疗的患者更有可能出现 AHO。这些结果强调需要优化痴呆症患者的药物治疗,尤其是合并症患者。